Novo Nordisk has given investors a better quarter, but not yet a clear return to growth. On November 4, the Danish pharmaceutical company reported DKK 79.2 billion in third-quarter sales, with improving Wegovy sales driven partly by the growing contribution of its oral obesity treatment. The results exceeded expectations and prompted management to raise its full-year forecast.
Yet the revised outlook still allows adjusted sales to decline by 2% in 2026. The company that helped build the modern obesity-drug market is improving its performance while competing in a market where Eli Lilly is expanding much faster.
The contrast is particularly striking because Lilly reported 39% revenue growth just six days earlier. Both companies are selling important metabolic medicines, but their financial trajectories are diverging. Novo’s results show that the Wegovy pill is becoming commercially meaningful while the injectable faces continued pressure.
The question is no longer what Novo might report on November 4. The numbers are available. The question is whether its improving commercial execution can produce sustained growth rather than another year of flat or declining adjusted sales.
Novo Raised Its Forecast, but the Low End Still Means a Decline
Novo’s updated financial guidance calls for adjusted sales growth between minus 2% and plus 2% at constant exchange rates. The company issued the same range for adjusted operating profit growth.
That represents an improvement from its previous forecast of minus 6% to zero growth. The revision reflects stronger expectations for GLP-1 medicine sales following the third-quarter results.
It is important to recognize the improvement. Moving from the possibility of a 6% decline toward a narrower range centered on zero suggests management has become more confident about the business’s near-term performance.
But the company is still not forecasting unequivocal growth. At the lower end of the range, Novo’s adjusted sales and adjusted operating profit would both finish 2026 below their prior-year levels.
That distinction matters for a pharmaceutical company whose valuation and market position were built during a period of extraordinary demand for semaglutide products.
In the third quarter itself, Novo recorded DKK 79.195 billion in net sales, up 6% in Danish kroner and 4% at constant exchange rates. The improvement was driven by continued GLP-1 volume growth in the United States and international markets, particularly in obesity treatment.
Total obesity sales reached DKK 26.146 billion, representing 22% growth at constant exchange rates. That is an important counterweight to the weaker performance of the injectable Wegovy franchise.
The company’s commercial position is therefore more complicated than a simple turnaround or continuing decline. Its obesity portfolio is growing, its pill is gaining traction and its revised outlook is better. But full-year adjusted growth has not yet been secured.
A raised forecast is not automatically a growth forecast. Novo’s new guidance makes that distinction unusually clear.
Wegovy Injectable Barely Moved. The Pill Became a Bigger Business.
Two product lines reveal much of what happened during the quarter.
Wegovy injectable generated DKK 20.407 billion in third-quarter sales. That was unchanged in Danish kroner from the comparable period a year earlier and represented a 2% decline at constant exchange rates.
In the second quarter, injectable Wegovy sales were DKK 19.484 billion, with year-on-year growth of 1% at constant exchange rates. The third-quarter result therefore shows higher sequential revenue but continued year-on-year pressure after adjusting for currency.
Revenue growth alone does not establish what happened to the number of patients using the injectable. Sales can be influenced by realized prices, rebates, geographic mix, inventory movements and changes in prescription volumes.
Novo’s regional results show why that distinction matters. Its U.S. injectable Wegovy sales declined at constant exchange rates, while international sales increased. A single worldwide number can hide considerably different regional patterns.
The Wegovy pill tells another story.
The oral formulation generated DKK 5.394 billion in third-quarter revenue, compared with DKK 3.218 billion in the second quarter. That increase is commercially meaningful for a treatment launched in the United States at the beginning of 2026.
By September 30, the pill had launched in four markets: the United States, United Arab Emirates, United Kingdom and Germany. Novo subsequently added Mexico, Spain, France and Poland, bringing the total to eight markets by the time of its November report.
The company also reported approximately 3.6 million U.S. prescriptions for the Wegovy pill during the third quarter and more than eight million cumulative prescriptions since launch. Prescription counts are not the same as unique patients, but they demonstrate the scale of adoption.
Novo says the Wegovy franchise remains the U.S. leader in new patient starts among branded obesity medicines. That is a narrower measure than worldwide revenue leadership, and the two should not be confused.
The central commercial question is whether oral semaglutide is expanding the number of people receiving obesity treatment or shifting some existing patients away from injectable products.
Some substitution between formulations is plausible, but the quarterly sales figures do not establish how much is occurring. New patients, switching patients, insurance coverage and cash-pay channels can all influence the observed results.
For now, the pill is providing a meaningful additional source of revenue while injectable Wegovy’s worldwide year-on-year sales growth remains weak.
The injection is still the larger business. The pill is now the more visibly expanding one.
Read the Footnotes: Adjusted Profit Versus Reported Profit
The third-quarter profit figures offer a warning about reading biotechnology earnings without examining the adjustments.
Novo reported adjusted operating profit of DKK 31.720 billion, an increase of 34% in Danish kroner and 27% at constant exchange rates.
Reported operating profit, however, was DKK 23.011 billion, a decline of 3% in Danish kroner and 9% at constant exchange rates.
Neither number is inherently wrong. They describe different aspects of the company’s financial performance.
Adjusted operating profit excludes specified exceptional or non-recurring items. Reported operating profit includes the accounting effects recognized under the applicable financial-reporting standards.
In Q3 2026, Novo recorded DKK 8.7 billion in non-cash impairment charges. Of that total, DKK 4.6 billion related to the investigational cardiovascular drug ziltivekimab and DKK 4.1 billion related to manufacturing-network right-sizing.
An impairment reflects a reduction in the recorded value of an asset. It does not mean the company spent the equivalent amount of cash during the quarter. It does, however, represent a financial consequence of lowered expectations about an asset’s future economic value.
The adjusted profit comparison also benefits from a different accounting effect. Novo recognized DKK 9 billion in company-wide transformation costs during the third quarter of 2025, creating a relatively favorable comparison base for this year’s adjusted profit growth.
The nine-month sales figures involve another major distinction.
For January through September 2026, Novo reported DKK 254.506 billion in net sales. Adjusted net sales were DKK 227.746 billion, reflecting the exclusion of a DKK 26.760 billion provision reversal associated with the U.S. 340B Drug Pricing Program.
That difference matters because reported nine-month sales increased 13% at constant exchange rates, while adjusted sales increased just 2%. The reported figure includes a substantial accounting benefit recognized earlier in the year, not simply higher recurring demand for medicines.
Investors should therefore distinguish quarterly sales, reported nine-month sales, adjusted sales and adjusted profit before concluding that the business has returned to its former growth trajectory.
The quarter is stronger than expected. The accounting footnotes explain why that conclusion is not the entire story.
Lilly’s 39% Revenue Growth Shows How Wide the Competitive Gap Has Become
Novo’s improving performance arrived less than a week after Eli Lilly reported a substantially faster rate of revenue growth.
On October 29, Lilly announced third-quarter revenue of $24.397 billion, an increase of 39% from the same quarter in 2025.
Mounjaro generated $10.723 billion, while Zepbound contributed $5.352 billion. Lilly’s oral obesity drug Foundayo recorded $184 million in quarterly sales as the company expanded its newer product portfolio.
Lilly also raised its 2026 full-year revenue guidance to between $91 billion and $92 billion. The contrast with Novo is striking: Lilly is forecasting substantial expansion while Novo is still working toward establishing consistent adjusted growth.
However, the two companies’ revenue growth percentages are not perfectly comparable. Novo’s cited adjusted sales growth is measured at constant exchange rates, while Lilly’s 39% increase reflects its reported U.S.-dollar revenue.
The businesses also differ in their product portfolios, regional exposures and accounting adjustments. A growth-rate comparison does not by itself establish market share or product-level superiority.
Still, the overall direction is difficult to overlook. Lilly reported worldwide volume growth of 53%, partially offset by a 15% decline in realized prices. Within the United States, volume increased 41%, while realized prices declined 7%.
These figures illustrate an important feature of the changing obesity-drug business. Lower prices do not necessarily prevent revenue growth when demand and prescription volumes increase substantially.
Lilly’s report also included approximately $900 million in quarterly benefits, primarily related to Jardiance milestone payments and favorable rebate and discount-estimate adjustments. Those financial items should not be mistaken for additional sales generated entirely through new obesity-drug prescriptions.
Grey Pepper examined Lilly’s product performance in its report on Mounjaro, Zepbound and Q3 2026 pricing trends.
The competition is also moving beyond injections. The market for oral GLP-1 treatments is becoming another important commercial battleground, as explored in our analysis of oral obesity-drug comparisons.
Novo’s Wegovy pill offers a meaningful commercial response, but one successful product line cannot settle the broader competitive question. The company must defend its injectable franchise while expanding oral sales, managing pricing pressure and maintaining investment in future treatments.
Lilly’s results show that strong volume growth can outweigh falling realized prices. Novo’s results show how difficult that balance can become once a previously dominant product enters a more competitive market.
What Comes Next: CagriSema, Pricing and the Search for Durable Growth
The quarterly results do not settle Novo’s longer-term outlook. Its next challenge is translating the Wegovy pill’s early momentum and the broader obesity portfolio into sustained adjusted sales growth.
The commercial rollout will be central. Novo has already expanded the pill into additional markets and is planning further launches. The size of those opportunities will depend on patient access, reimbursement, local pricing, distribution and competitive alternatives.
U.S. pricing remains especially important. Lower realized prices can reduce revenue even when prescription volumes rise. For obesity medicines, rebates, insurance negotiations and the growing importance of cash-pay channels make the distinction between list prices and realized prices essential.
The company also has a developing pipeline that could alter its competitive position.
In its November 4 announcement, Novo reported that the 1.0/1.0 mg CagriSema regimen achieved approximately 21% weight loss at week 68 in the REDEFINE 9 trial.
CagriSema combines semaglutide with cagrilintide, an amylin analogue. Novo is preparing for a potential U.S. launch in early 2027, subject to regulatory approval.
The trial result provides additional clinical evidence for the combination strategy. It does not establish regulatory approval, guaranteed commercial success or a definitive competitive advantage over every existing obesity medicine.
Novo is also advancing other metabolic candidates, including oral therapies and multi-receptor approaches, as the obesity-drug market becomes increasingly crowded.
The company’s near-term task is therefore both commercial and scientific. It needs to sustain the Wegovy pill’s uptake, address pricing pressure on injectable semaglutide and demonstrate that its pipeline can provide additional treatments with attractive clinical and commercial profiles.
Investors should monitor several measurable developments: the rate of new patient adoption for oral Wegovy, the performance of injectable sales in the United States, changes in realized prices, and whether adjusted growth strengthens as new products enter more markets.
The full-year guidance remains the clearest financial benchmark. A range from minus 2% to plus 2% is better than the previous outlook, but it is not equivalent to a return to the double-digit growth that once defined Novo’s obesity-drug business.
The November quarter offered encouraging signs. Total obesity sales increased, the pill became a larger contributor and management revised its expectations upward.
At the same time, injectable Wegovy’s year-on-year sales remained under pressure, reported operating profit declined and a major competitor continued expanding at a far faster rate.
Novo did not report a failed quarter. It reported a better one that still leaves fundamental questions unanswered.
The company’s challenge now is to turn improvement into durable growth. Until that happens, the fact that an upgraded forecast still permits declining sales remains the defining financial detail.
Primary source: Novo Nordisk financial report for January 1 to September 30, 2026, published November 4, 2026.
Previous-quarter comparison: Novo Nordisk Q2 2026 financial report, SEC Form 6-K, August 4, 2026.
Competitor financial results: Eli Lilly third-quarter 2026 financial results, October 29, 2026.
Additional reporting: Reuters — Novo raises its outlook as Wegovy pill sales gain momentum, November 4, 2026.
